NEW YORK (TheStreet) -- Two biotechs and two China-based Internet companies highlight our stocks to watch today, as they carry strong technical momentum.

Image placeholder title

ADXS data by YCharts

1. Advaxis (ADXS) - Get Report

Advaxis continues its impressive uptrend, up 10-fold since its breakout in December. It's currently in a three-day pennant after spiking over 25% in just a few days on news of FDA-clearance to conduct a Phase 2 drug study involving cervical cancer. On Thursday it rallied for 93 cents to $28.52, and if it can get through $29.50, it could see $32.50-to-$33 quickly, with a secondary target at $39-to-$40.

Image placeholder title

JUNO data by YCharts

2. Juno Therapeutics (JUNO)

Juno Therapeutics has been in a steep ascent since mid-May, and is now challenging its post-IPO highs near $66. The stock, which has been very volatile since its December IPO, exploded for $6.78, or 11.8%, to $64 on Thursday, on 2.7 million shares. That followed news earlier in the week of the company's acquisition of private Boston-area biotech X-BODY Inc. A move through $66 could take the stock to $70 next.

Image placeholder title

WBAI data by YCharts

3. Limited (WBAI) - Get Report

China-based, which provides online sports lottery services, is in a three-month up-channel, reversing off its spike low in March at $7.31. The stock gained $1 to $23 on Thursday on no news, continuing its breakout from its recent falling wedge. Targets are $27 and then the channel top and lateral resistance at $30.

Image placeholder title

XNET data by YCharts

4. Xunlei Limited (XNET) - Get Report

Xunlei, which recently spiked up and then pulled back and held support in a one-week consolidation, is on the move again. The China-based digital media company rallied 10% on Wednesday, and then another 3.6% on Thursday, up 39 cents to $11.22 on 836,900 shares traded. Look for a test of the recent high at $12-to-$12.15, and if it gets through that, the target is in the $14-to-$15 zone.

See video chart analysis on these stocks.

This article is commentary by an independent contributor. At the time of publication, the author held no positions in the stocks mentioned.